Anacor wins big in dermatitis market of many millions
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals jumped 55.9% to close at $131.93 per share on 13 July on positive top-line Phase III results for the atopic dermatitis (AD) drug crisaborole, which could be safer than other topical treatments for millions of patients – mostly children – with mild-to-moderate forms of the skin disease.
You may also be interested in...
Atopic Dermatitis: Ziarco Hopes Oral Therapy Will Trump Injectable Biologics
UK biotech Ziarco’s orally active histamine H4-antagonist shows potential in atopic dermatitis in proof-of-concept studies, and the firm may seek capital for further studies before it is Phase III ready.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.